Erleada 60mg Tablet

Like other anticancer medicines, Erleada 60mg Tablet has some mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects

Fatigue
Joint and muscle pain
Loss of appetite
Rashes and itching on the skin
High blood pressure
Swelling
Hot flashes
Weight loss
Diarrhea
Broken bone
Vomiting and nausea

Severe side effects

Dizziness & sweating
Trouble with speaking
Problem in vision
Chest pain and faster heart rate
Difficulty in normal breathing
Severe skin allergic reactions
Lung inflammation

Erleada 60mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Erleada 60mg Tablet is an anticancer medication consisting of a salt ingredient known as Apalutamide. This medicine acts by preventing androgen (male hormone) production in males. It inhibits an enzyme known as CYP17, which is responsible for androgen production. This process slows down the multiplication rate and stops the progression of prostate cancer.

It is advised not to miss any scheduled dosage of Erleada 60mg Tablet. In case you miss a dose, consult your doctor immediately. Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Erleada 60mg Tablet is an anticancer medication consisting of a salt ingredient known as Apalutamide. Erleada 60mg Tablet is used to treat prostate cancer in men. So, it is not safe to use for women and children.

Your healthcare expert must measure your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Erleada 60mg Tablet can cause fluctuations in their levels.

Inform your doctor if you have diabetes or any heart, liver, or kidney problems before taking Erleada 60mg Tablet.

Use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erleada 60mg Tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.

Erleada is not recommended in patients with a history of seizures, any brain injury, or a recent stroke (within one year).

Yu, A., & Ackaert, O. (2023). Bioequivalence clinical trial simulation: a case study of apalutamide administered in applesauce versus whole tablets. AAPS Open, 9(1), 15.
Tohi, Y., Kobayashi, K., Daizumoto, K., Sekino, Y., Fukuhara, H., Niigawa, H., & Sugimoto, M. (2025). Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. Japanese Journal of Clinical Oncology, 55(6), 643-649.
Nguyen, M. D., Modestine, J. R. D., Djoua, Y., Gorobets, O., Vinh-Hung, V. & Verschraegen, C. F. (2025). Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series. Anticancer Research, 45(7), 3127-3136.
Boegemann, M., Bennamoun, M., Dourthe, L. M. Encarnacion, J. A., Hegele, A., Hellmis, E. & Kramer, G. (2025). Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer. BMC cancer, 25(1), 1119.
Yue, W., Li, C., Wang, T., You, J., Sun, J., Liu, J., & Padanilam, B. J. (2025). Circadian rhythm-related miR-6883-5p suppresses enzalutamide-resistant prostate cancer. Non-coding RNA Research.
Roy, S., Malone, S., Wing, K., Chowdhury, S., Kishan, A. U., Sun, Y., & Saad, F. (2024). Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial. JAMA network open, 7(10), e2439434-e2439434.